Glutathione metabolism in cancer progression and treatment resistance

被引:876
|
作者
Bansal, Ankita [1 ]
Simon, M. Celeste [1 ,2 ]
机构
[1] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA
来源
JOURNAL OF CELL BIOLOGY | 2018年 / 217卷 / 07期
基金
美国国家卫生研究院;
关键词
GAMMA-GLUTAMYL-TRANSPEPTIDASE; TRANSCRIPTION FACTOR NRF2; CYSTINE/GLUTAMATE ANTIPORTER; OXIDATIVE DAMAGE; LUNG-CANCER; PATHWAY; CELLS; TRANSFERASE; ACTIVATION; INHIBITION;
D O I
10.1083/jcb.201804161
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glutathione (GSH) is the most abundant antioxidant found in living organisms and has multiple functions, most of which maintain cellular redox homeostasis. GSH preserves sufficient levels of cysteine and detoxifies xenobiotics while also conferring therapeutic resistance to cancer cells. However, GSH metabolism plays both beneficial and pathogenic roles in a variety of malignancies. It is crucial to the removal and detoxification of carcinogens, and alterations in this pathway can have a profound effect on cell survival. Excess GSH promotes tumor progression, where elevated levels correlate with increased metastasis. In this review, we discuss recent studies that focus on deciphering the role of GSH in tumor initiation and progression as well as mechanisms underlying how GSH imparts treatment resistance to growing cancers. Targeting GSH synthesis/utilization therefore represents a potential means of rendering tumor cells more susceptible to different treatment options such as chemotherapy and radiotherapy.
引用
收藏
页码:2291 / 2298
页数:8
相关论文
共 50 条
  • [41] The influence of glutathione metabolism on multidrug resistance in MRP-overexpressing cells
    Twentyman, P
    Bagrij, T
    DRUG RESISTANCE UPDATES, 1998, 1 (02) : 121 - 127
  • [42] Sphingolipid metabolism and complement signaling in cancer progression
    Janneh, Alhaji H.
    Atkinson, Carl
    Tomlinson, Stephen
    Ogretmen, Besim
    TRENDS IN CANCER, 2023, 9 (10): : 782 - 787
  • [43] Lipid metabolism in cancer progression and therapeutic strategies
    Fu, Yan
    Zou, Tiantian
    Shen, Xiaotian
    Nelson, Peter J.
    Li, Jiahui
    Wu, Chao
    Yang, Jimeng
    Zheng, Yan
    Bruns, Christiane
    Zhao, Yue
    Qin, Lunxiu
    Dong, Qiongzhu
    MEDCOMM, 2021, 2 (01): : 27 - 59
  • [44] METABOLISM OF GLUTATHIONE
    BINKLEY, F
    NATURE, 1951, 167 (4257) : 888 - 889
  • [45] Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
    Al Hmada, Youssef
    Brodell, Robert T.
    Kharouf, Naji
    Flanagan, Thomas W.
    Alamodi, Abdulhadi A.
    Hassan, Sofie-Yasmin
    Shalaby, Hosam
    Hassan, Sarah-Lilly
    Haikel, Youssef
    Megahed, Mosaad
    Santourlidis, Simeon
    Hassan, Mohamed
    CANCERS, 2024, 16 (02)
  • [46] Defining the Key Mediators of Breast Cancer Progression and Treatment Resistance in the triple Negative Subtype
    Mathe, Andrea
    Wong-Brown, Michelle
    Morten, Brianna C.
    Braye, Stephen G.
    Locke, Warwick J.
    Stirzaker, Clare
    Clark, Susan J.
    Scott, Rodney
    Avery-Kiejda, Kelly A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 9 - 9
  • [47] Glutathione as a potential marker of tamoxifen resistance in breast cancer
    Hamadneh, Yazan I.
    AlWahsh, Mohammad
    Alrawabdeh, Jawad
    Hergenroder, Roland
    Dahabiyeh, Lina A.
    Hamadneh, Lama
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Glutathione in redox regulation of the development of cancer cell resistance
    Kalinina, Elena
    Chernov, Nikolay
    Novichkova, Maria
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 120 : S137 - S137
  • [49] CALCIUM AND PHOSPHATE METABOLISM IN DISSEMINATED BREAST CANCER - EFFECTS OF SITE, PROGRESSION OR REGRESSION, AND HORMONAL TREATMENT
    GARDNER, B
    GORDAN, GS
    LOKEN, HF
    THOMAS, AN
    CANCER CHEMOTHERAPY REPORTS, 1962, (16): : 299 - 303
  • [50] LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer
    Blazquez, Raquel
    Rietkoetter, Eva
    Wenske, Britta
    Wlochowitz, Darius
    Sparrer, Daniela
    Vollmer, Elena
    Mueller, Gunnar
    Seegerer, Julia
    Sun, Xueni
    Dettmer, Katja
    Barrantes-Freer, Alonso
    Stange, Lena
    Utpatel, Kirsten
    Bleckmann, Annalen
    Treiber, Hannes
    Bohnenberger, Hanibal
    Lenz, Christof
    Schulz, Matthias
    Reimelt, Christian
    Hackl, Christina
    Grade, Marian
    Bueyuektas, Deram
    Siam, Laila
    Balkenhol, Marko
    Stadelmann, Christine
    Kube, Dieter
    Krahn, Michael P.
    Proescholdt, Martin A.
    Riemenschneider, Markus J.
    Evert, Matthias
    Oefner, Peter J.
    Klein, Chistoph A.
    Hanisch, Uwe K.
    Binder, Claudia
    Pukrop, Tobias
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (11) : 3170 - 3183